Cepheid Q4 Revenues Rise 71 Percent as It Trims Net Loss | GenomeWeb
This article has been updated to include comments from a conference call and a stock quote.
 
NEW YORK (GenomeWeb News) – Cepheid reported today that its fourth-quarter revenues rose 71 percent, driven by increasing adoption of its GeneXpert system among hospitals outside of the Veterans Administration system, as the firm cut its net loss 36 percent year over year.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: genetic target for urothelial bladder cancer treatment, and more.

At the Conversation, the University of Oxford's Michael Macklay writes that learning genetic risk of disease is a personal decision.

Two dozen scientific organizations have endorsed the March for Science, according to ScienceInsider.

Researchers in Japan describe a chimpanzee with a chromosomal abnormality similar to human Down syndrome, Mashable reports.